拉脱维亚 - 拉脱维亚文 - Zāļu valsts aģentūra

sandoz d.d., slovenia - sorafenibs - apvalkotā tablete - 200 mg

拉脱维亚 - 拉脱维亚文 - Zāļu valsts aģentūra

zentiva, k.s., czech republic - sorafenibs - apvalkotā tablete - 200 mg

欧盟 - 拉脱维亚文 - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - krūts audzējs - antineoplastiski līdzekļi - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

拉脱维亚 - 拉脱维亚文 - Zāļu valsts aģentūra

sandoz d.d., slovenia - sorafenibs - apvalkotā tablete - 400 mg

拉脱维亚 - 拉脱维亚文 - Zāļu valsts aģentūra

egis pharmaceuticals plc, hungary - sorafenibs - apvalkotā tablete - 200 mg

拉脱维亚 - 拉脱维亚文 - Zāļu valsts aģentūra

lv system service sia, latvia - sorafenibs - apvalkotā tablete - 200 mg

欧盟 - 拉脱维亚文 - EMA (European Medicines Agency)

amgen europe bv - sotorasib - karcinoma, nesīkšūnu plaušas - antineoplastiski līdzekļi - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

欧盟 - 拉脱维亚文 - EMA (European Medicines Agency)

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastiski līdzekļi - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

欧盟 - 拉脱维亚文 - EMA (European Medicines Agency)

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastiski līdzekļi - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.

拉脱维亚 - 拉脱维亚文 - Zāļu valsts aģentūra

norameda uab, lithuania - enzalutamīds - kapsula, mīkstā - 40 mg